Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756845 · ClinicalTrials.gov registry record · Phase 1
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02756845 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 15 participants.
The verdict
NCT02756845, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection
Interventions
- DRUG Talimogene Laherparepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2022-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756845
The ClinicalTrials.gov registry entry for NCT02756845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talimogene Laherparepvec is the first listed.
NCT02756845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756845 about?
NCT02756845 is a clinical study titled "Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors". This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection
What is the current status of trial NCT02756845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-08-16. Estimated completion is 2022-11-29.
What interventions are being tested in trial NCT02756845?
The interventions under investigation include: Talimogene Laherparepvec (DRUG).
Who is sponsoring clinical trial NCT02756845?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.